These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8684530)

  • 61. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
    Boelaert JR; van Roost GF; Vergauwe PL; Verbanck JJ; de Vroey C; Segaert MF
    Clin Nephrol; 1988 May; 29(5):261-6. PubMed ID: 3293856
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Efficacy and safety of long-term and low-dose desferrioxamine therapy against hyperaluminemia and the clinical symptoms associated with hyperaluminemia in patients undergoing maintenance hemodialysis].
    Kuramochi G
    Nihon Jinzo Gakkai Shi; 1989 Mar; 31(3):267-73. PubMed ID: 2739124
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
    Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
    Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
    [No Abstract]   [Full Text] [Related]  

  • 65. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR; Barnett MD; Brozovic B; Cattell WR; Ackrill P; McAlister J; Nimmon C
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ultrafiltrable aluminium after very low doses of desferrioxamine.
    Canteros A; Díaz-Corte C; Fernández-Martín JL; Gago E; Fernández-Merayo C; Cannata J
    Nephrol Dial Transplant; 1998 Jun; 13(6):1538-42. PubMed ID: 9641189
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
    Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
    J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.
    Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY
    Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Aluminum and iron overload in chronic dialysis.
    Ackrill P; Day JP; Ahmed R
    Kidney Int Suppl; 1988 Mar; 24():S163-7. PubMed ID: 3283407
    [No Abstract]   [Full Text] [Related]  

  • 73. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA; Campbell F; Savory J; Chevalier RL
    Int J Pediatr Nephrol; 1987; 8(1):21-4. PubMed ID: 3583552
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevention and treatment of aluminum overload in uremic patients: long-term results.
    Canavese C; Thea A; Pacitti A; Salomone M; Mangiarotti G; Segoloni G; Stratta P; Gurioli L; Constantini S; Giordini R
    Clin Nephrol; 1989 Apr; 31(4):169-74. PubMed ID: 2714022
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The use of chelating agents in the treatment of aluminum overload.
    Domingo JL
    J Toxicol Clin Toxicol; 1989; 27(6):355-67. PubMed ID: 2697761
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
    Douthat WG; Acuña Aguerre G; Fernández Martín JL; Mouzo R; Cannata Andía JB
    Nephrol Dial Transplant; 1994; 9(10):1431-4. PubMed ID: 7816256
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol.
    Hood SA; Clark WF; Hodsman AB; Bolton CF; Cordy PE; Anderson C; Leung F
    Am J Nephrol; 1984; 4(6):369-74. PubMed ID: 6517116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.